These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 30904418)
21. Long-term control of leptomeningeal disease after radiation therapy and nivolumab in a metastatic melanoma patient. Wu RC; Newman W; Patanowitz L; Branstetter BF; Amankulor N; Tarhini AA Immunotherapy; 2020 Aug; 12(11):763-769. PubMed ID: 32571131 [No Abstract] [Full Text] [Related]
22. Stereotactic radiosurgery and anti-PD-1 + CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases. Dohm AE; Nakashima JY; Kalagotla H; Jiang SX; Tang JD; Bhandari M; Kim Y; Graham JA; Khushalani NI; Forsyth PA; Etame AB; Liu JK; Tran ND; Vogelbaum MA; Wuthrick EJ; Yu HM; Oliver DE; Ahmed KA Eur J Cancer; 2023 Oct; 192():113287. PubMed ID: 37657227 [TBL] [Abstract][Full Text] [Related]
23. Immunotherapy in managing metastatic melanoma: which treatment when? Amaral T; Meraz-Torres F; Garbe C Expert Opin Biol Ther; 2017 Dec; 17(12):1523-1538. PubMed ID: 28891339 [TBL] [Abstract][Full Text] [Related]
24. Radiosurgery/stereotactic radiotherapy in combination with immunotherapy and targeted agents for melanoma brain metastases. Trino E; Mantovani C; Badellino S; Ricardi U; Filippi AR Expert Rev Anticancer Ther; 2017 Apr; 17(4):347-356. PubMed ID: 28277101 [TBL] [Abstract][Full Text] [Related]
25. Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies. Vosoughi E; Lee JM; Miller JR; Nosrati M; Minor DR; Abendroth R; Lee JW; Andrews BT; Leng LZ; Wu M; Leong SP; Kashani-Sabet M; Kim KB BMC Cancer; 2018 Apr; 18(1):490. PubMed ID: 29703161 [TBL] [Abstract][Full Text] [Related]
26. Robotic Stereotactic Radiosurgery in Melanoma Patients with Brain Metastases under Simultaneous Anti-PD-1 Treatment. Trommer-Nestler M; Marnitz S; Kocher M; Rueß D; Schlaak M; Theurich S; von Bergwelt-Baildon M; Morgenthaler J; Jablonska K; Celik E; Ruge MI; Baues C Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30205431 [TBL] [Abstract][Full Text] [Related]
28. Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma. Sundahl N; Seremet T; Van Dorpe J; Neyns B; Ferdinande L; Meireson A; Brochez L; Kruse V; Ost P Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):828-835. PubMed ID: 30951807 [TBL] [Abstract][Full Text] [Related]
29. Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases? Franceschini D; Franzese C; Navarria P; Ascolese AM; De Rose F; Del Vecchio M; Santoro A; Scorsetti M Cancer Treat Rev; 2016 Nov; 50():1-8. PubMed ID: 27566962 [TBL] [Abstract][Full Text] [Related]
30. Case records of the Massachusetts General Hospital. Case 21-2013. A 68-year-old man with metastatic melanoma. Sullivan RJ; Lawrence DP; Wargo JA; Oh KS; Gonzalez RG; Piris A N Engl J Med; 2013 Jul; 369(2):173-83. PubMed ID: 23841733 [No Abstract] [Full Text] [Related]
31. Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis. Amaral T; Tampouri I; Eigentler T; Keim U; Klumpp B; Heinrich V; Zips D; Paulsen F; Gepfner-Tuma I; Skardelly M; Tatagiba M; Tabatabai G; Garbe C; Forschner A Immunotherapy; 2019 Mar; 11(4):297-309. PubMed ID: 30606066 [TBL] [Abstract][Full Text] [Related]
32. Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs. Swe T; Kim KB Clin Exp Metastasis; 2018 Aug; 35(5-6):503-520. PubMed ID: 30019239 [TBL] [Abstract][Full Text] [Related]
33. The role of systemic therapies in the management of melanoma brain metastases. Lyle M; Long GV Curr Opin Oncol; 2014 Mar; 26(2):222-9. PubMed ID: 24434634 [TBL] [Abstract][Full Text] [Related]
35. Melanoma therapy: Check the checkpoints. Furue M; Kadono T J Dermatol; 2016 Feb; 43(2):121-4. PubMed ID: 26813076 [TBL] [Abstract][Full Text] [Related]
36. BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis. Patel KR; Chowdhary M; Switchenko JM; Kudchadkar R; Lawson DH; Cassidy RJ; Prabhu RS; Khan MK Melanoma Res; 2016 Aug; 26(4):387-94. PubMed ID: 27223498 [TBL] [Abstract][Full Text] [Related]
37. What to Do When Anti-PD-1 Therapy Fails in Patients With Melanoma. Mooradian MJ; Sullivan RJ Oncology (Williston Park); 2019 Apr; 33(4):141-8. PubMed ID: 30990567 [TBL] [Abstract][Full Text] [Related]
38. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Mathew M; Tam M; Ott PA; Pavlick AC; Rush SC; Donahue BR; Golfinos JG; Parker EC; Huang PP; Narayana A Melanoma Res; 2013 Jun; 23(3):191-5. PubMed ID: 23462208 [TBL] [Abstract][Full Text] [Related]
39. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]